Randomized Controlled Trial of Olanzapine for the Control of Chemotherapy-inducedVomiting in Children Receiving Highly Emetogenic Chemotherapy
Study of Olanzapine in Children Receiving Chemotherapy for Hematopoietic Stem Cell Transplant (HSCT)
Sponsor: The Hospital for Sick Children Research Institute
Enrolling: Male and Female Patients
IRB Number: AAAS8602
U.S. Govt. ID: NCT03118986
Contact: Diane George, MD: 212-305-2466 / dg2039@cumc.columbia.edu
Additional Study Information: This research study is to find out whether adding olanzapine to standard antiemetics will be helpful in controlling chemotherapy-induced vomiting (CINV) in children receiving high-dose cyclophosphamide for Blood/Bone Marrow Transplant (BMT) conditioning.
This study is closed
Investigator
Diane George, MD
Do You Qualify?
Are you or your child between the ages of 2.5-18? Yes No
Do you or your child have a planned Allogeneic Hematopoietic stem cell transplant? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Diane George, MD
dg2039@cumc.columbia.edu
212-305-2466
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE